News Sentiment

MEDP sentiment intelligence

Medpace Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 538.23 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-3.5% over one week, +15.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Why Medpace (MEDP) Dipped More Than Broader Market Today

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -3.5% Price reacting lower
Trend fit Trend inactive 15.2% over four weeks
Fair value 38.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 30
Negative 14

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 7
simplywall.st 6
ACCESS Newswire 5
Stock Titan 4
Investing.com 2
marketscreener.com 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 14
Regulatory and legal 8
Analyst action 8

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Market source Direct company coverage

Why Medpace (MEDP) Dipped More Than Broader Market Today

Medpace (MEDP) shares dipped 1.49% today, underperforming the broader market, despite an impressive 15.17% gain over the past month. Investors are eagerly anticipating its upcoming earnings report on July 22, 2026, with projected EPS up 31.61% and revenue up 15.95% year-over-year

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 17:15
Source
Market source
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (MEDP) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased Medpace securities prior to April 22, 2025, and still hold them, to join the investigat

Tone
Negative 28/100
Event
Regulatory and legal
Published
09 Jul 2026 11:00
Source
ACCESS Newswire
Investing.com Direct company coverage

Baird downgrades Medpace stock rating to neutral, raises target to $547

Baird has downgraded Medpace Holdings Inc. (NASDAQ:MEDP) from Outperform to Neutral, while increasing its price target to $547.00 from $477.00. The downgrade comes despite the stock's 69% surge over the past year, as its current trading price of $546 is nearly identical to Baird'

Tone
Negative 28/100
Event
Analyst action
Published
09 Jul 2026 06:39
Source
Investing.com
Investing.com Nigeria Direct company coverage

Baird downgrades Medpace stock rating to neutral, raises target to $547 By Investing.com

Baird has downgraded Medpace (NASDAQ:MEDP) stock from Outperform to Neutral, while increasing its price target to $547 from $477. The downgrade is primarily due to the stock's significant rally, now trading near Baird's new price target, and a need for the firm to substantially r

Tone
Negative 38/100
Event
Analyst action
Published
08 Jul 2026 16:11
Source
Investing.com Nigeria
marketscreener.com Direct company coverage

Baird Downgrades Medpace to Neutral From Outperform, Adjusts PT to $547 From $477

Baird has downgraded Medpace Holdings (MEDP) from an "Outperform" rating to "Neutral," while simultaneously increasing its price target for the company from $477 to $547. This adjustment reflects a modified outlook by the firm on Medpace's stock. The article also provides a brief

Tone
Negative 40/100
Event
Analyst action
Published
08 Jul 2026 12:10
Source
marketscreener.com
The Globe and Mail Direct company coverage

Medpace Growth Trends Show How CRO Demand Is Shifting in 2026

Medpace Holdings (MEDP) is experiencing a shift in demand for its clinical research organization (CRO) services in 2026, with an uneven distribution across therapeutic areas and a longer conversion cycle for awards into revenue. Despite these challenges, Medpace's full-service mo

Tone
Positive 61/100
Event
Earnings
Published
07 Jul 2026 18:39
Source
The Globe and Mail
Investing.com Direct company coverage

Jefferies downgrades Medpace stock rating on valuation concerns

Jefferies downgraded Medpace Holdings Inc. (NASDAQ:MEDP) to Hold from Buy, citing significant valuation concerns despite raising the price target to $515.00 from $490.00. The stock is currently trading above this target, and analysts note it is overvalued, with several downward e

Tone
Negative 27/100
Event
Analyst action
Published
07 Jul 2026 18:10
Source
Investing.com
marketscreener.com Direct company coverage

Medpace Shares Fall After Jefferies Downgrade

Medpace Holdings, Inc. shares dropped following a downgrade from Jefferies. The article, published on July 7, 2026, also provides recent analyst ratings and financial forecasts for the company. Medpace operates as a full-service clinical contract research organization specializin

Tone
Negative 29/100
Event
Analyst action
Published
07 Jul 2026 17:13
Source
marketscreener.com
Investing.com Canada Direct company coverage

Jefferies downgrades Medpace stock rating on valuation concerns By Investing.com

Jefferies downgraded Medpace Holdings Inc. (NASDAQ:MEDP) to Hold from Buy due to valuation concerns, despite raising its price target to $515.00 from $490.00. The stock is currently trading significantly above this new target, and InvestingPro data indicates it is overvalued, wit

Tone
Negative 30/100
Event
Analyst action
Published
07 Jul 2026 08:41
Source
Investing.com Canada
The Globe and Mail Direct company coverage

Medpace Stock Outlook Turns on Backlog Quality and Cancellations

Medpace Holdings, Inc. (MEDP) faces a near-term outlook where backlog quality and cancellations are more critical than headline growth, despite having stable margins and liquidity. While the company's backlog provides revenue visibility, its book-to-bill ratio remains below 1.0X,

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 15:39
Source
The Globe and Mail
Finviz Direct company coverage

MEDP - Medpace Holdings Inc Latest SEC Filings

This article provides the latest SEC filings information for Medpace Holdings Inc (MEDP), along with comprehensive financial data, key performance indicators, and company statistics. It details various financial ratios, insider and institutional ownership, profitability margins,

Tone
Positive 61/100
Event
Market update
Published
04 Jul 2026 16:41
Source
Finviz
TradingView Direct company coverage

Enterprise value to revenue forward of Medpace Holdings, Inc. – NASDAQ:MEDP

This article focuses on the enterprise value to revenue forward metric for Medpace Holdings, Inc. (NASDAQ: MEDP). It appears to be a financial data point presented on TradingView without additional commentary or analysis within the provided content. The surrounding text primarily

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 16:41
Source
TradingView
Moomoo Direct company coverage

Here's Why Medpace Holdings (NASDAQ:MEDP) Has Caught The Eye Of Investors

Medpace Holdings (NASDAQ:MEDP) has demonstrated strong financial performance, reporting a significant return on capital employed (ROCE) of 34% and increasing its capital employed by 65%. This indicates an efficient and growing business that is effectively reinvesting its earnings

Tone
Positive 76/100
Event
Earnings
Published
04 Jul 2026 04:39
Source
Moomoo
Stock Titan Direct company coverage

Medpace (NASDAQ: MEDP) director converts restricted stock units into common shares

Medpace Holdings director Cornelius P. McCarthy III converted 28 restricted stock units (RSUs) into common shares, adding to his direct holdings of 10,352 shares. He still holds 56 unvested RSUs. This transaction, detailed in a Form 4 filing, is an exercise of derivative securiti

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Medpace (MEDP) director converts 36 RSUs into common shares

Medpace Holdings director Brian T. Carley converted 36 restricted stock units (RSUs) into common stock on June 30, 2026. This transaction, revealed in a Form 4 SEC filing, brings his total common stock holdings to 32,825 shares, with 71 RSUs remaining. The RSUs are part of a 143-

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Medpace (MEDP) director Robert O. Kraft exercises 33 RSUs, holds 955 shares

Medpace Holdings, Inc. director Robert O. Kraft exercised 33 restricted stock units (RSUs) into common shares on June 30, holding 955 common shares and 64 remaining RSUs after the transaction. These RSUs are part of a 130-unit grant from November 28, 2025, vesting in four equal i

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
The National Law Review Direct company coverage

MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) and certain officers for alleged violations of federal securities laws. The lawsuit claims Medpace made materially false and misleading statements regarding its

Tone
Negative 28/100
Event
Regulatory and legal
Published
01 Jul 2026 20:39
Source
The National Law Review
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Medpace Holdings, Inc. (NASDAQ:MEDP) for potential corporate wrongdoing. The firm encourages investors who purchased Medpace securities before April 22, 2025, and still hold them, to connect to assist with the investigation. Thi

Tone
Negative 30/100
Event
Regulatory and legal
Published
30 Jun 2026 16:09
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Medpace Holdings, Inc. (NASDAQ:MEDP) stockholders who purchased shares before April 22, 2025. The investigation focuses on possible corporate wrongdoing by Medpace and its officers/directors. The la

Tone
Negative 19/100
Event
Regulatory and legal
Published
29 Jun 2026 15:39
Source
ACCESS Newswire
TradingView Direct company coverage

Price to book forward of Medpace Holdings, Inc. – NASDAQ:MEDP

This page displays the "Price to book forward" metric for Medpace Holdings, Inc. (NASDAQ: MEDP). It appears to be a financial data point provided by TradingView, with additional data from ICE Data Services and FactSet. The page is primarily a placeholder for this specific financi

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 14:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Medpace Holdings, Inc. – NASDAQ:MEDP

This article provides the "Price to sales forward" metric for Medpace Holdings, Inc. (NASDAQ: MEDP). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company's stock.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 20:40
Source
TradingView
TradingKey Direct company coverage

Medpace Holdings Inc (MEDP) Valuation: PE, PB & Fair Value Analysis

Medpace Holdings Inc (MEDP) has a current valuation score of 9.87, ranking 7th out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 32.49, which is significantly below its recent high but above its recent low. However, relevant data for P

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 08:09
Source
TradingKey
TradingView Direct company coverage

Enterprise value to EBITDA forward of Medpace Holdings, Inc. – NASDAQ:MEDP

This article provides financial data for Medpace Holdings, Inc. (NASDAQ: MEDP), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, offering a snapshot of this key valuation multiple without

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Medpace Holdings, Inc. – LSX:A2APTV

This article provides a financial snapshot of Medpace Holdings, Inc. (LSX:A2APTV) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates the market status as closed with no recent trades. The content emphasizes financial data and market informa

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 23:09
Source
TradingView
TradingView Direct company coverage

Medpace Holdings, Inc. Actuals & Estimates (NASDAQ:MEDP)

Medpace Holdings, Inc. (MEDP) stock has seen significant growth, with a 1.40% increase in the last 24 hours, 12.29% over the past week, and 65.21% over the last year. Analysts have set a price target range of $400.00 to $495.00 for MEDP. The company is scheduled to release its ne

Tone
Positive 77/100
Event
Analyst action
Published
26 Jun 2026 08:40
Source
TradingView